ATE266662T1 - Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten - Google Patents

Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten

Info

Publication number
ATE266662T1
ATE266662T1 AT99931496T AT99931496T ATE266662T1 AT E266662 T1 ATE266662 T1 AT E266662T1 AT 99931496 T AT99931496 T AT 99931496T AT 99931496 T AT99931496 T AT 99931496T AT E266662 T1 ATE266662 T1 AT E266662T1
Authority
AT
Austria
Prior art keywords
kappa
indanderivates
active ingredients
inhibitors containing
inhibitors
Prior art date
Application number
AT99931496T
Other languages
English (en)
Inventor
Yoichi Nunokawa
Takashi Nakatsuka
Masayuki Saitoh
Keiichi Abe
Original Assignee
Daiichi Suntory Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Suntory Pharma Co Ltd filed Critical Daiichi Suntory Pharma Co Ltd
Application granted granted Critical
Publication of ATE266662T1 publication Critical patent/ATE266662T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT99931496T 1998-07-22 1999-07-22 Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten ATE266662T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20692998 1998-07-22
PCT/JP1999/003938 WO2000005234A1 (en) 1998-07-22 1999-07-22 NF-λB INHIBITORS CONTAINING INDAN DERIVATIVES AS THE ACTIVE INGREDIENT

Publications (1)

Publication Number Publication Date
ATE266662T1 true ATE266662T1 (de) 2004-05-15

Family

ID=16531400

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99931496T ATE266662T1 (de) 1998-07-22 1999-07-22 Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten

Country Status (6)

Country Link
US (1) US6734180B1 (de)
EP (1) EP1018514B1 (de)
AT (1) ATE266662T1 (de)
DE (1) DE69917201T2 (de)
ES (1) ES2219033T3 (de)
WO (1) WO2000005234A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021206A1 (en) * 1999-09-17 2001-03-29 Suntory Limited PREVENTIVES OR REMEDIES FOR MYOCARDITIS, DILATED CARDIOMYOPATHY AND CARDIAC INSUFFICIENCY CONTAINING NF-λB INHIBITORS AS THE ACTIVE INGREDIENT
WO2002036547A1 (en) * 2000-11-01 2002-05-10 Ajinomoto Co.,Inc. Cyclopropanecarboxylic acid amide compounds and medicinal use thereof
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
EP1375465A4 (de) 2001-04-03 2006-01-11 Eisai Co Ltd Cyclooctanonderivat und cyclodecanonderivat und deren verwendung
US6933410B2 (en) 2002-03-08 2005-08-23 Novartis Ag Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
DE10222895A1 (de) * 2002-05-23 2003-12-11 Bosch Gmbh Robert Hochdruckspeicher für Kraftstoffeinspritzsysteme mit integriertem Druckregelventil
CA2488342A1 (en) * 2002-06-05 2003-12-18 Institute Of Medicinal Molecular Design, Inc. Therapeutic drug for diabetes
WO2003103658A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
EA009523B1 (ru) * 2002-06-05 2008-02-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Ингибиторы в отношении активации ар-1 и nfat
US7626042B2 (en) 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
BR0311605A (pt) * 2002-06-06 2005-02-22 Boehringer Ingelheim Pharma Compostos de amida de ácido 3-aminotieno[2,3-b]piridina-2-carboxìlico substituìdo e processos para preparação e seus usos
AU2003242103A1 (en) * 2002-06-06 2003-12-22 Institute Of Medicinal Molecular Design, Inc Antiallergic agents
EA010835B1 (ru) * 2002-06-10 2008-12-30 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Лекарственное средство для лечения рака
EP1535609A4 (de) * 2002-06-10 2009-01-07 Inst Med Molecular Design Inc Nf-kb-aktivierungshemmer
US20060035944A1 (en) * 2002-06-11 2006-02-16 Susumu Muto Remedies for neurodegenerative diseases
US7572770B2 (en) * 2002-06-27 2009-08-11 University Of Zurich Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
US7959161B2 (en) * 2002-11-12 2011-06-14 Nok Corporation Rubber-like elastic part
US7425580B2 (en) 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
DE102005061170A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, acyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
DE102005061171A1 (de) 2005-12-21 2007-07-05 Bayer Healthcare Ag Neue, cyclisch substituierte Furopyrimidin-Derivate und ihre Verwendung
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
JPWO2008020622A1 (ja) * 2006-08-17 2010-01-07 杏林製薬株式会社 新規なチエノ［２，３−ｄ］ピリミジン化合物
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
CN102260270A (zh) * 2010-05-28 2011-11-30 中国科学院上海药物研究所 N-(2-甲基呋喃[2，3-d]嘧啶-4-基)丙烯酰胺、其制备方法及其用途
EP3049086A4 (de) 2013-09-27 2017-02-22 Nimbus Iris, Inc. Irak-inhibitor und verwendungen davon
US20190112317A1 (en) * 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
FR3066761B1 (fr) * 2017-05-23 2020-10-30 Centre Nat Rech Scient Nouveaux composes inhibiteurs des canaux ioniques
US20200325148A1 (en) * 2017-12-21 2020-10-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
EP3728201A1 (de) * 2017-12-21 2020-10-28 Gliapharm SA Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen mit demenz
CN113801033B (zh) * 2021-11-16 2022-02-08 苏州欣诺科生物科技有限公司 2-氨基茚满或其衍生物的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470182A (en) * 1967-02-09 1969-09-30 Sandoz Ag 4-amino-substituted quinazolines
DE2901843A1 (de) 1979-01-18 1980-07-31 Hoechst Ag Verfahren zur herstellung von carbonsaeureamiden und peptiden
US4501735A (en) 1983-12-05 1985-02-26 Warner-Lambert Company N6-(1- and 2-benzocycloalkyl) adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
DE3623944A1 (de) * 1986-07-16 1988-02-11 Thomae Gmbh Dr K Neue benzolsulfonamido-indanylverbindungen, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH02184649A (ja) 1989-01-11 1990-07-19 Sumitomo Metal Ind Ltd ホルムアルデヒドの製法
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
US5137879A (en) 1990-03-30 1992-08-11 Dowelanco Furopyrimidin-4-imine derivatives
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69636997T2 (de) * 1995-05-12 2007-07-12 Anges MG Inc., Ibaraki HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
AU726058B2 (en) * 1995-09-01 2000-10-26 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
JPH11512399A (ja) * 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法
JPH09227561A (ja) * 1996-02-21 1997-09-02 Tanabe Seiyaku Co Ltd キサンチン誘導体
JPH1087492A (ja) 1996-06-25 1998-04-07 Ono Pharmaceut Co Ltd 一酸化窒素産生阻害剤
JPH1087491A (ja) * 1996-07-26 1998-04-07 Asahi Chem Ind Co Ltd 転写調節因子阻害剤

Also Published As

Publication number Publication date
EP1018514A4 (de) 2001-05-30
ES2219033T3 (es) 2004-11-16
WO2000005234A1 (en) 2000-02-03
EP1018514B1 (de) 2004-05-12
DE69917201T2 (de) 2005-05-04
EP1018514A1 (de) 2000-07-12
DE69917201D1 (de) 2004-06-17
US6734180B1 (en) 2004-05-11

Similar Documents

Publication Publication Date Title
DE69917201D1 (de) Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
ES2182234T3 (es) Inhibidores de metaloproteasa.
PT1204322E (pt) Fungicidas
NO950297D0 (no) Prolinamidderivater
ES2091068T3 (es) Combinaciones de productos activos fungicidas.
UY27447A1 (es) Mezclas herbicidas basadas sobre 3-feniluracilos
NO307336B1 (no) 2-[(Dihydro)pyrazolyl-3'-oksylmetylen]anilider, anvendelse derav, samt middel inneholdende forbindelsen og mellomprodukter for fremstilling av forbindelsen
EA200100529A1 (ru) Нестероидные ингибиторы воспалений
NO991494L (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
DK0941221T3 (da) Substituerede dihydrobenzofuraner som PDE-inhibitorer
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
TR200401676T4 (tr) Fungusid olarak aktif bileşik kombinasyonları
ID28716A (id) Komposisi antimikroba
DE60032470D1 (de) Heilmittel die sulfopyranosylacylglycerolderivate enthalten
ATE399545T1 (de) Mittel zur verringerung der eigeweidefette
ES2169242T3 (es) 2-amino-benzoxazinonas para el tratamiento de infecciones virales.
TR199901017A2 (xx) B�cek ilac� terkibi.
DE69825977D1 (de) Antivirale mittel
DK1349457T3 (da) Væskeformige antimikrobemidler
NO20070421L (no) Radiosensitiviserende middel
DK0676399T3 (da) Methotrexaderivater
NO20014382L (no) Nye immunoundertrykkende middel
EP1270561A4 (de) Inhibitor der biosynthese des brassinosteroids
ATE154243T1 (de) Hemmstoff der blutgefässhypertrophie
PT1140932E (pt) Derivados de 1,8-benzonaftiridina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties